DIRS.INFO The most relevant business & tech news

☆ Greenlight's David Einhorn builds new stake in this gambling name. Here's what else he bought
▼ + stars: | 2024-04-24 | by ( Adam Jeffery | ) www.cnbc.com time to read: +2 min

Greenlight Capital's David Einhorn continued to pick up new stocks in the first quarter, including Penn Entertainment , as the longtime value investor struggles to find opportunities in the volatile market. He established the stake at an average cost of $22.69 per share, but the stock has fallen to $17.44 as of Wednesday. Still, Einhorn said sports betting, if executed right, could take the shares much higher. "Were the market to credit PENN with merely 15% of DraftKings' value, that segment alone would be worth $20 per share." Q4 buyer's strike Einhorn had stopped building new stock positions at one point in the fourth quarter, saying he was on a "buyer's strike" due to worries about intensifying geopolitical risks.

Persons: Greenlight Capital's David Einhorn, Einhorn, PENN, he's, Greenlight, — CNBC's Leslie Picker Organizations: Penn Entertainment, CNBC, Barstool Sports, Cornell grad, Greenlight Capital, HP, Roivant Sciences, Liberty Global

☆ Vivek Ramaswamy ends presidential campaign
▼ + stars: | 2024-01-15 | by ( Aaron Pellish | Kaitlan Collins | ) edition.cnn.com time to read: +11 min

CNN —Biotech entrepreneur Vivek Ramaswamy ended his campaign for the 2024 Republican presidential nomination Monday night after a disappointing finish in the Iowa caucuses. From Vivek Ramaswamy 2024 Presidential Campaign Ramaswamy appears in a sixth-grade musical performance at his school in Sharonville, Ohio, in 1997. From Vivek Ramaswamy 2024 Presidential Campaign Ramaswamy speaks at the Forbes Under 30 Summit in Philadelphia in 2015. Demetrius Freeman/The Washington Post/Getty Images Ramaswamy and Nikki Haley participate in the first Republican presidential debate in August 2023. Win McNamee/Getty Images Ramaswamy talks to members of the media after the first Republican presidential debate.

Persons: Vivek Ramaswamy, we’ve, ”, Ramaswamy, Donald Trump, ” Ramaswamy, “, Anna Moneymaker, Tony Jones, Network Ramaswamy, Instagram Ramaswamy, Gilbert Carrasquillo, Karthik, Apoorva, Angelo Merendino, Anthony Anex, Shutterstock Ramaswamy, Mark Peterson, Alex Brandon, Maddie McGarvey, Jon Cherry, Walter Waligura, John Tully, Arjun, Apoorva Ramaswamy, Michael M, Ramaswamy's, Vek, Demetrius Freeman, Nikki Haley, Win McNamee, Scott Olson, Ramaswamy claps, Maansi Srivastava, Trump, Tucker Carlson’s, Ronna McDaniel, “ We’ve, Kim Reynolds, stagnating, caucusgoers, CNN’s Gregory Krieg, Kaitlan Collins Organizations: CNN — Biotech, Trump, “, Street Journal, Republican, Conservative Political, Conference, Cincinnati Enquirer, USA, Network, Jesuit, Xavier High School, Harvard University, Forbes, Swiss Economic, Ohio Republican, Washington Post, Rifle, Bloomberg, Getty, New York Times, Liberty National Summit, Ohio State University, Iowa State Fairgrounds, BMI, White, Inc, Fox News, Yale University, Roivant Sciences, Management, Republican Party, GOP, RNC, Fair, Gov, Des Moines Register, NBC, CNN New, South Carolina Gov Locations: Iowa, Des Moines , Iowa, New Hampshire, “ America, of, New York, Sharonville , Ohio, Philadelphia, Columbus , Ohio, Interlaken, Switzerland, Cincinnati, Indianapolis, Windham , New Hampshire, Independence , Iowa, Clive , Iowa, “, Cincinnati , Ohio, Ohio, CNN New Hampshire, Indian, Ukraine, Russia, Israel, China, Taiwan, Iraq, Afghanistan

☆ Stocks making the biggest moves premarket: Tyson Foods, Boeing, Monday.com and more
▼ + stars: | 2023-11-13 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines before the bell: Monday.com — Shares of the project management company jumped 10% after Monday.com reported a strong quarter and issued a rosy forecast. Monday.com reported third-quarter earnings and revenue of 64 cents per share on revenue of $189.2 million. Tyson Foods — The food products company fell 3.3% in premarket trading after Tyson's fiscal fourth-quarter revenue came in weaker than expected. Boeing — Shares rose 3.25% after Emirates Airlines announced the purchase of 95 Boeing aircraft for a total of $52 billion. TripAdvisor — Shares of the online booking company added 2.3% after Bernstein upgraded TripAdvisor to outperform from market perform.

Persons: Monday.com, FactSet, Matt Gline, Roche, Bernstein, GitLab, Henry Schein, — CNBC's Michelle Fox, Alex Harring, Jesse Pound, Pia Singh Organizations: Tyson, Boeing, Emirates Airlines, Sciences, Roivant Sciences, Revenue, HP Inc, Citi

☆ Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
▼ + stars: | 2023-10-23 | by ( Adrià Calatayud | ) www.wsj.com time to read: 1 min

Roche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs. Photo: Philipp Schmidli/Bloomberg NewsRoche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences , a company started by Republican presidential candidate Vivek Ramaswamy , and Pfizer in a deal worth more than $7 billion. The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.

Persons: Philipp Schmidli, Vivek Ramaswamy, Roche Organizations: pharma, Bloomberg, Roche Holding, Roivant Sciences, Republican, Pfizer, Telavant Holdings, Telavant’s Locations: Swiss, U.S, Japan

☆ Stocks making the biggest moves premarket: Chevron, Apple, Walgreens Boots Alliance and more
▼ + stars: | 2023-10-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

Chevron , Hess — Chevron shares slumped more than 2% after the oil giant said its buying smaller rival Hess in an all-stock deal totaling $53 billion, or $171 a share. Hess shares moved slightly higher. Walgreens Boots Alliance — The pharmacy operator rose nearly 3% after JPMorgan upgraded Walgreens Boots Alliance shares to overweight from neutral. Salesforce — The software giant lost nearly 2% after Piper Sandler downgraded shares to neutral from overweight, citing heightened execution and M & A risks. Bank of America downgraded Alcoa to a neutral rating and slashed its price target, citing concerns of a near-term earnings decline.

Persons: Hess, Stonepeak, Piper Sandler, Roche, —, Jesse Pound Organizations: Hess, Chevron, Apple, Global Times, Walgreens, Alliance, JPMorgan, Roivant Sciences, Pfizer, Telavant Holdings, Citi, Evercore, Alcoa, Bank of America Locations: Chevron, China

☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
▼ + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.

Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan

Sept 26 (Reuters) - Shares of Immunovant (IMVT.O) surged nearly 80% on Tuesday, after early-stage data from its experimental antibody treatment exceeded analysts' expectations. Immunovant is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases. Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease in healthy adults. Shares of Roivant Sciences (ROIV.O), Immunovant's largest shareholder with a 56.5% stake, according to LSEG data, also rose 17.5% to $12. The positive data from IMVT-1402 could give Roivant another "potentially blockbuster" candidate to transact, after its experimental treatment for bowel disease, Jefferies analyst Dennis Ding said.

Persons: J.P, Morgan, Brian Cheng, drugmakers Johnson, Johnson, Hytrulo, Immunovant, transact, Jefferies, Dennis Ding, Bhanvi, Krishna Chandra Organizations: UCB, Roivant Sciences, Thomson Locations: United States, York, IMVT, Bengaluru

But a person who worked closely with Ramaswamy said, "He thinks people are put on this earth to serve him." Roivant attracted investors including Masayoshi Son's SoftBank Vision Fund, Peter Thiel's Founders Fund, and the hedge fund Viking Global Investors. Former Roivant employees said Ramaswamy worked hard and expected the same of others. McLaughlin called the employee's recollection "inaccurate," adding that Ramaswamy "has never once raised his voice or used bad language with employees." At Roivant, Ramaswamy kept his politics largely to himself, former employees said.

Persons: Vivek Ramaswamy, Ramaswamy, He's, Donald Trump, Mike Pence, Nikki Haley, Ron DeSantis, Trump, George Soros, didn't, Taco Bell, he's, —, Vivek, Tricia McLaughlin, he'd, McLaughlin, takeout, Forbes, Vivek doesn't, they've, Roivant, Masayoshi, Peter Thiel's, Thiel, JD Vance, Bill Ackman, who'd, . Ramaswamy, Erik Gordon, Vance, John Phillips, Joyce Rosely, Phillips, Anson Frericks, they'd, Rosely, Frericks, They're, they're, Eric Balchunas, Todd Rosenbluth, Rosenbluth, Christopher Lenzo, Brandon Bell, Vivek Ramaswamy's, Katherine Long, Jack Newsham, Meghan Morris Organizations: pharma, Army Rangers, Biotech, Republican, nab, GOP, of Education, FBI, Nuclear Regulatory Commission, Federal Reserve, Florida, Roivant Sciences, General Electric, Yale Law School, Army, Rangers, Harvard, Yale, Fund, Viking Global, Leerink Partners, GlaxoSmithKline, Forbes, Big Pharma, Japan's Sumitomo Pharma Co, ., University of Michigan, FDA, US, Yale Law, ESG, The, Texas, Indiana, BlackRock, Vanguard, Bloomberg Intelligence, Fair, SEC Locations: Mexico, FiveThirtyEight, Roivant, Patagonia, Iowa, New York, Ohio, The Lever

☆ Factbox: Who is Vivek Ramaswamy, Republican presidential hopeful?
▼ + stars: | 2023-08-23 | by ( Tim Reid | ) www.reuters.com time to read: +3 min

Aug 23 (Reuters) - Vivek Ramaswamy, a multimillionaire former biotech executive, has a chance to build on the attention he has been getting in the race for the 2024 Republican presidential nomination at Wednesday night's debate. Ramaswamy says he voted for a libertarian in the 2004 presidential election, but did not vote in 2008, 2012 or 2016. The book raised Ramaswamy's profile among conservatives, and he began his rapid ascension as a right-wing star. REPUBLICAN PRESIDENTIAL CAMPAIGNRamaswamy declared his campaign for president in February, at a time when his bid looked like a long shot. Although a Hindu, Ramaswamy has been telling voters that the U.S. is based on "Christian values" and "Judeo-Christian values" and has described himself as an American nationalist.

Persons: Vivek Ramaswamy, Ramaswamy, Donald Trump, Ron DeSantis, Trump, Tim Reid, Ross Colvin, Andy Sullivan Organizations: MIDWEST Ramaswamy, Harvard University, Yale Law School, Yale, Roivant Sciences, Forbes, Harvard, Republican, Democratic, Inc, REPUBLICAN, FBI, Department of Education, Service, Ukraine, Thomson Locations: Ohio, India, Iowa, Florida, American, Kiev, Russia, Ukraine

☆ Roivant in talks to sell bowel disease drug to Roche in over $7 bln deal - WSJ
▼ + stars: | 2023-07-13 | by ( ) www.reuters.com time to read: +1 min

July 13 (Reuters) - Biotech company Roivant Sciences (ROIV.O) is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche (ROG.S) in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday. The sale of the drug could be announced in the coming days, the report said, citing people familiar with the matter. Roivant's experimental drug, RVT-3101, is under clinical trials for the treatment of moderate-to-severe ulcerative colitis, a long-term condition where the colon and rectum become inflamed, as well as a type of inflammatory bowel disease known as Crohn's disease. Roivant declined to comment, whereas Roche did not immediately respond to a Reuters request for comment. Reporting by Shivani Tanna and Sriparna Roy in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: Roche, Roivant, Shivani Tanna, Sriparna Roy, Shailesh Organizations: - Biotech, Roivant Sciences, Wall Street, Thomson Locations: Bengaluru

☆ Ramaswamy Investments Seem at Odds With His Position on ‘Woke’ Culture
▼ + stars: | 2023-07-07 | by ( Trip Gabriel | More About Trip Gabriel | ) www.nytimes.com time to read: +1 min

Mr. Ramaswamy has argued that such goals are a distraction from earning a profit, and that social objectives should be left to elected officials. Tricia McLaughlin, a senior adviser to Mr. Ramaswamy, said that he did not manage his own stock portfolio. “Vivek’s stock portfolio is independently managed by a third party. The filing reported that Mr. Ramaswamy owned up to a $25 million investment in Rumble, the video platform that styles itself a refuge for right-wing commentators shunned elsewhere. Mr. Ramaswamy, 37, is a Cincinnati native who holds degrees from Harvard and Yale.

Persons: Ramaswamy, Tricia McLaughlin, Vivek, ” Ms, McLaughlin, “, Mr, Donald J, Trump Organizations: Republican, Harvard, Yale, Roivant Sciences Locations: cryptocurrency, Cincinnati

☆ JPMorgan highlights its top stock picks heading into July
▼ + stars: | 2023-07-07 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

JPMorgan updated its list of top stock picks for July, as investors are now eyeing the second half of the year. To kick off this month, JPMorgan added Domino's Pizza and Dollar General to its focus list. Domino's Pizza stock has slipped more than 3% in 2023, but it's still rated overweight by JPMorgan analyst John Ivankoe. Holdovers from previous iterations of the focus list include tech stocks Amazon and Microsoft . JPMorgan removed multimedia stock Avid Technology from its focus list earlier this week.

Persons: John Ivankoe, Stifel, Brian Cheng, Morgan Stanley Organizations: JPMorgan, Nasdaq, Sciences, Microsoft, Federal Trade Commission, Amazon Prime, Avid Technology Locations: OpenAI's

☆ Trump says he's 'pleased' to see Vivek Ramaswamy was even with Pence and ahead of Haley in a recent poll
▼ + stars: | 2023-05-05 | by ( Brent D. Griffiths | ) www.businessinsider.com time to read: +3 min

The former president said he was "pleased" to see entrepreneur Vivek Ramaswamy doing so well. A political newcomer, Ramaswamy performed very well in a recent poll. "I am pleased to see that Vivek Ramaswamy is doing so well in the most recent Republican Primary Poll, CBS YouGov," Trump wrote on his social media platform, Truth Social. RealClearPolitics' more raw average has Ramaswamy in fifth behind DeSantis, Pence, and Haley respectively. In response to Trump's praise, Ramaswamy senior adviser Tricia McLaughlin told Insider, "We're 10 weeks in and just getting warmed up."

April 11 (Reuters) - A U.S. appeals court handed Moderna Inc (MRNA.O) a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp (ABUS.O) patent related to the companies' legal fight over Moderna's blockbuster COVID-19 vaccines. The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention. Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, and the board invalidated it in 2019. Arbutus separately sued Pfizer and BioNTech for patent infringement last week over their COVID-19 shots, in a lawsuit that also does not include the canceled patent. The Federal Circuit case is Arbutus Biopharma Corp v. ModernaTX Inc, U.S. Court of Appeals for the Federal Circuit, No.

☆ Ramaswamy Reaches for the Presidency
▼ + stars: | 2023-02-23 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

Donald Trump proved that you don’t need to hold elective office before you try for the Oval Office, and entrepreneur Vivek Ramaswamy is taking that as inspiration as he announced Tuesday that he’s running for the Republican presidential nomination in 2024. He has a chance to make a contribution to the race even if he is a long shot. The 37-year-old Ohio native attended Harvard and earned a law degree from Yale, but don’t hold that against him. In 2014 he also founded a biotechnology firm, Roivant Sciences , and served as CEO until 2021. We’ve come to know him over the years through his contributions to these pages, which are provocative and well-wrought even if we disagree.

[1/2] People pose with syringe with needle in front of displayed Moderna logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/IllustrationFeb 15 (Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc (MRNA.O), the Department of Justice told a Delaware federal court on Tuesday. Moderna made the same argument last year in an unsuccessful bid to win an early dismissal of the lawsuit. Both Moderna and Pfizer Inc (PFE.N) have been the target of multiple patent lawsuits over their COVID vaccines, including a lawsuit brought by Moderna against Pfizer in August. The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No.

☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
▼ + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +14 min

Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.

Dec 1 (Reuters) - Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market. The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest. SVB Securities analyst David Risinger says the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity. RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger. Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25% stake in another jointly held company called Priovant.

Search resuls for: "Roivant Sciences"

18 mentions found